AffaMed Therapeutics Announced Top-Line Results From Real-World Study In China Evaluating The Safety And Efficacy Of DEXTENZA In Patients After Cataract Surgery; NOTE: AffaMed Therapeutics Has A Licensing Agreement With Ocular Therapeutix, Inc.
Portfolio Pulse from Benzinga Newsdesk
AffaMed Therapeutics announced positive top-line results from a real-world study in China evaluating the safety and efficacy of DEXTENZA in patients after cataract surgery. The trial met its primary and secondary endpoints, demonstrating a significant reduction of ocular inflammation and pain. AffaMed has a licensing agreement with Ocular Therapeutix, Inc. (NASDAQ: OCUL) for the development and commercialization of DEXTENZA in Greater China, South Korea, and certain ASEAN markets.
October 31, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AffaMed's positive results from the DEXTENZA study could potentially boost Ocular Therapeutix's revenues and reputation, as they have a licensing agreement for the drug's development and commercialization in several Asian markets.
The positive results from the DEXTENZA study are likely to increase the drug's demand, which could lead to increased revenues for Ocular Therapeutix due to their licensing agreement with AffaMed. This could also enhance the company's reputation in the market, potentially attracting more partnerships and boosting its stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80